文献速递肾癌与肾肿瘤

双药联合治疗在 favourable-risk 晚期肾细胞癌中的系统评价与Meta分析

A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk.
PubMed 文献 · Urology · 2021-08-28

该系统评价与Meta分析纳入7项II/III期随机对照试验共1214例 favourable-risk 晚期肾细胞癌患者,比较一线双药联合治疗与舒尼替尼单药。

要点

  • favourable-risk 晚期肾细胞癌一线双药联合较舒尼替尼单药无总生存获益。
  • 双药联合无进展生存无显著获益,但排除ICI-ICI方案后PFS获益显著。
  • 启动双药联合前需与患者充分讨论替代治疗选择。

核心结论

  • 在 favourable-risk 晚期肾细胞癌患者中,双药联合治疗与舒尼替尼单药相比无总生存获益。
  • 需更长随访以明确是否存在潜在总生存获益。
  • 启动双药联合前应仔细讨论替代管理方案。

研究设计与样本

  • 系统评价Medline、EMBASE和Cochrane Central Register of Controlled trials。
  • 纳入一线、姑息性双药联合治疗 favourable-risk 晚期肾细胞癌的II/III期随机对照试验。
  • 共纳入7项II/III期随机对照试验,N=1214。
  • 采用逆方差随机效应模型进行Meta分析。
  • 进行排除ICI-ICI联合方案的敏感性分析。

主要发现

  • favourable-risk 组双药联合与舒尼替尼单药的总生存无显著差异(HR 0.96,95%CI 0.73-1.26,P=0.79)。
  • 排除ICI-ICI方案的敏感性分析中总生存仍无显著获益(HR 0.99,95%CI 0.69-1.43,P=0.96)。

临床怎么用

  • favourable-risk 晚期肾细胞癌患者一线选择双药联合需权衡缺乏总生存获益的证据。
  • 与患者讨论时需说明双药联合在 favourable-risk 组的总生存和无进展生存结果。
  • 排除ICI-ICI方案后无进展生存获益显著,可作为个体化决策参考。

局限性

  • 需更长随访以明确潜在总生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the impact of first-line dual therapy involving immune checkpoint inhibitors (ICI) on survival outcomes in patients with advanced renal cell carcinoma (aRCC) of International Metastatic RCC Database Consortium favourable-risk. MATERIALS AND METHODS: Systematic review of Medline, EMBASE, and Cochrane Central Register of Controlled trials were conducted to select all phase II/III randomized clinical trials involving first-line, palliative-intent dual therapy in aRCC patients of favourable-risk. Inverse-variance with random-effects model was used for meta-analysis. Sensitivity analysis with exclusion of immune checkpoint inhibitors (ICI)-ICI combination was conducted. Study outcomes were overall survival (OS) and progression free survival (PFS). RESULTS: Seven phase II/III randomized controlled trials (N = 1214) were included in the meta-analysis. There were no significant OS differences detected in the favourable-risk group on dual therapy in comparison to sunitinib monotherapy (HR 0.96, 95%CI 0.73-1.26, P = .79). Sensitivity analysis also did not show significant OS benefit when excluding ICI-ICI regimen (HR 0.99, 95%CI 0.69-1.43, P = .96). PFS was not shown to have significant benefit for dual therapy in the favourable-risk group (HR 0.75, 95%CI 0.50-1.13, P = .17), but it met statistical significance when ICI-ICI regimen was excluded from the analysis (HR 0.63, 95%CI 0.50-0.79, P <.001). CONCLUSION: There was no OS benefit when comparing dual therapy vs sunitinib monotherapy in aRCC favourable-risk group. Longer follow-up would be required to definitively detect potential OS benefit, if any. Careful patient-clinician discussion of alternative management options are required prior to initiating dual-therapy in all aRCC favourable-risk group.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Kartolo A, Holstead RG, Duran I, et al. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk. Urology. 2021. PMID: 34461142. doi:10.1016/j.urology.2021.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。